Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Neoplasms 3Arthritis, Rheumatoid 3Graft vs Host Disease 2Myelodysplastic Syndromes 1Multiple Myeloma 1Leukemia 1Hematologic Neoplasms 1Arthritis 1Anemia, Refractory 1

Interventions

Tacrolimus 29fludarabine phosphate 21Methotrexate 21Cyclophosphamide 21Mycophenolic Acid 18Busulfan 15Antilymphocyte Serum 14Whole-Body Irradiation 13Sirolimus 12fludarabine 11Peripheral Blood Stem Cell Transplantation 11Cyclosporine 9thymoglobulin 8Melphalan 8Hematopoietic Stem Cell Transplantation 6Granulocyte Colony-Stimulating Factor 6Filgrastim 6Rituximab 5Pentostatin 5Methylprednisolone 5Thiotepa 4Stem Cell Transplantation 4Radiotherapy 4Cyclosporins 4ruxolitinib 3Vorinostat 3Transplantation 3Flow Cytometry 3Etoposide 3merphos 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Graft vs Host Disease × Abatacept × Clear all
NCT01743131 2025-12-11

Abatacept as GVHD Prophylaxis Phase 2

Boston Children's Hospital

Phase 2 Completed
186 enrolled 14 charts 1 FDA

Graft vs Host Disease, Neoplasms

NCT03680092 2025-10-02

Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation

University of California, San Diego

Phase 2 Completed
43 enrolled 10 charts
Other hematologic neoplasm

Graft vs Host Disease, Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡